Altimmune Inc (ALT) Stock Price, Quote & News

Company Profile

Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.

Industry: Biotechnology

Sector: Healthcare

Phone: 240 654 1450

Website: altimmune.com

Address:

910 Clopper Road, Suite 201S, Gaithersburg, United States

denzo2 Jul. 16 at 10:48 PM

$ALT If anybody wants to buy my 4000 shares at $5 ( small profit).. let me know..thanks

2 · Reply

PashaGainz Jul. 16 at 10:05 PM

$ALT Hey family, I know I’ve been MIA. I’ve just been working a lot lately. Honestly, there really isn’t much to say right now. We’ve done all the due diligence we can with everything that’s been put in front of us so far. At this point it’s just a waiting game. We have 4 to 6 potentially massive catalysts over the next 12 months and that’s what I’m focused on. I couldn’t care less what the stock does day to day or even week to week because that’s never been my style of investing. I’ll keep buying when I can, keep averaging my cost down if the opportunity is there, and let the chips fall where they may once these catalysts start playing out. My conviction hasn’t changed one bit. I’m still extremely bullish on $ALT.

4 · Reply

Hatrak1 Jul. 16 at 9:48 PM

$ALT Sorry, had to correct the math ! 🤷‍♂️😁

1 · Reply

Hatrak1 Jul. 16 at 9:43 PM

$ALT The only thing more annoying is you ! 😁

0 · Reply

LeeroyJenkins2 Jul. 16 at 9:39 PM

$ALT

0 · Reply

LeeroyJenkins2 Jul. 16 at 9:38 PM

$ALT cheapies are expensive!

0 · Reply

Hatrak1 Jul. 16 at 9:29 PM

$ALT Yeah bro, That's pretty funny ! 🤣

1 · Reply

Chalutz Jul. 16 at 9:27 PM

$ALT The only thing more annoying is when people continually post Bought more cheapies today. Thanks for cheapies…..blah, blah, blah

0 · Reply

7Bstmde7B Jul. 16 at 9:01 PM

$ALT He’s so funny! Been here for over 2.5 years long, just find it amusing that every time this one goes up a few poont and down a few points, someone has to comment how they sold at the ”top” or ”bought the dip”. I hop you bought a lot, because a 5% dip is 0.15 c per share! laughable! Long and

0 · Reply

MRD85 Jul. 16 at 9:01 PM

$ALT

0 · Reply

Altimmune initiated with an Outperform at Leerink

2026-06-22T10:31:03.000Z - 24 days ago

Altimmune initiated with an Outperform at Leerink

Jun 10, 2026, 8:00 AM EDT - 5 weeks ago

Altimmune Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 4, 2026, 12:50 PM EDT - 6 weeks ago

Altimmune Transcript: Jefferies Global Healthcare Conference 2026

2026-05-28T16:27:37.000Z - 7 weeks ago

Altimmune reports 48-week data from IMPACT Phase 2b trial of pemvidutide

May 28, 2026, 11:00 AM EDT - 7 weeks ago

Pemvidutide Demonstrates Significant Metabolic Improvements in Patients with MASH in New 48‑Week IMPACT Phase 2b Data Presented at EASL 2026

May 27, 2026, 8:30 AM EDT - 7 weeks ago

Altimmune to Participate in Upcoming Investor Conferences

May 27, 2026, 8:00 AM EDT - 7 weeks ago

New IMPACT Phase 2b Data Highlight Concurrent Improvements Across Multiple Non-Invasive Markers and qFibrosis-Measured Fibrosis Regression with Pemvidutide in MASH at EASL 2026

2026-05-18T15:36:37.000Z - 2 months ago

Altimmune price target lowered to $20 from $25 at H.C. Wainwright

May 14, 2026, 7:00 AM EDT - 2 months ago

Altimmune Slides: Corporate presentation

2026-05-14T09:47:49.000Z - 2 months ago

Altimmune price target lowered to $11 from $14 at Citizens

May 13, 2026, 8:30 AM EDT - 2 months ago

Altimmune Earnings Call Transcript: Q1 2026

May 13, 2026, 8:30 AM EDT - 2 months ago

Altimmune Earnings release: Q1 2026

May 13, 2026, 8:30 AM EDT - 2 months ago

Altimmune Quarterly report: Q1 2026

2026-05-13T11:59:47.000Z - 2 months ago

Altimmune reports Q1 EPS (18c), consensus (25c)

May 13, 2026, 7:30 AM EDT - 2 months ago

Altimmune Announces First Quarter 2026 Financial Results and Business Update

May 13, 2026, 7:15 AM EDT - 2 months ago

Altimmune to Present Results of Pemvidutide in MASH in an Oral Presentation and Multiple Poster Presentations at EASL Congress 2026

May 6, 2026, 7:30 AM EDT - 2 months ago

Altimmune to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026

2026-04-27T19:56:05.000Z - 2 months ago

Altimmune management to meet with Piper Sandler

Apr 27, 2026, 7:00 AM EDT - 2 months ago

Altimmune Announces Closing of $225 Million Oversubscribed Public Offering of Securities

2026-04-24T09:16:13.000Z - 2 months ago

Altimmune upgraded to Neutral from Sell at Goldman Sachs

2026-04-23T11:06:36.000Z - 3 months ago

Altimmune 64.25M share Spot Secondary priced at $3.00

Apr 22, 2026, 11:25 PM EDT - 3 months ago

Altimmune Announces Pricing of $225 Million Oversubscribed Public Offering of Securities

2026-04-22T20:28:30.000Z - 3 months ago

Altimmune announces common stock offering, no amount given

Apr 22, 2026, 4:19 PM EDT - 3 months ago

Altimmune Announces Proposed Underwritten Public Offering of Securities

Apr 16, 2026, 8:30 AM EDT - 3 months ago

Altimmune Transcript: AGM 2026

2026-03-18T20:00:19.000Z - 4 months ago

Altimmune initiated with a Buy at Truist

Mar 17, 2026, 8:00 AM EDT - 4 months ago

Altimmune Proxy statement: Proxy Filing

2026-03-16T16:15:11.000Z - 4 months ago

Altimmune price target raised to $25 from $12 at H.C. Wainwright

Mar 12, 2026, 10:30 AM EDT - 4 months ago

Altimmune Transcript: Barclays 28th Annual Global Healthcare Conference

Mar 11, 2026, 9:20 AM EDT - 4 months ago

Altimmune Transcript: Leerink Global Healthcare Conference 2026

Mar 10, 2026, 2:15 PM EDT - 4 months ago

Altimmune Transcript: The Citizens Life Sciences Conference 2026

Mar 9, 2026, 7:00 AM EDT - 4 months ago

Altimmune Slides: Corporate presentation

2026-03-06T13:40:07.000Z - 4 months ago

Altimmune price target lowered to $13 from $18 at B. Riley

Mar 6, 2026, 7:00 AM EST - 4 months ago

Altimmune Proxy statement: Proxy Filing

Mar 5, 2026, 8:30 AM EST - 4 months ago

Altimmune Earnings Call Transcript: Q4 2025

Mar 5, 2026, 8:30 AM EST - 4 months ago

Altimmune Annual report: Q4 2025

Mar 5, 2026, 8:30 AM EST - 4 months ago

Altimmune Earnings release: Q4 2025

2026-03-05T12:14:56.000Z - 4 months ago

Altimmune reports Q4 EPS (27c), consensus (24c)

Mar 5, 2026, 7:00 AM EST - 4 months ago

Altimmune Announces Fourth Quarter and Full-year 2025 Financial Results and Business Updates

Feb 26, 2026, 7:30 AM EST - 5 months ago

Altimmune to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026

2026-02-20T14:12:05.000Z - 5 months ago

Altimmune management to meet with Piper Sandler

2026-02-13T14:55:31.000Z - 5 months ago

Altimmune initiated with a Buy at Titan Partners

Feb 3, 2026, 1:27 PM EST - 5 months ago

Obesity stocks slump on Novo's underwhelming 2026 sales forecast

AMGN GPCR LLY NVO PFE VKTX

Jan 29, 2026, 5:54 PM EST - 6 months ago

Altimmune Announces Closing of $75 Million Registered Direct Offering of Common Stock

Jan 27, 2026, 9:25 PM EST - 6 months ago

Altimmune Announces Pricing of $75 Million Registered Direct Offering of Common Stock

Jan 5, 2026, 7:30 AM EST - 6 months ago

Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH

Dec 19, 2025, 8:00 AM EST - 7 months ago

Altimmune Transcript: Study Result

Dec 19, 2025, 8:00 AM EST - 7 months ago

Altimmune Press release: Study Result

Dec 19, 2025, 8:00 AM EST - 7 months ago

Altimmune Slides: Study Result

Dec 19, 2025, 6:42 AM EST - 7 months ago

Altimmune's drug for a type of liver disease shows benefits in mid-stage study

Dec 19, 2025, 6:30 AM EST - 7 months ago

Altimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b MASH Trial

Dec 3, 2025, 2:30 PM EST - 8 months ago

Altimmune Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 1, 2025, 7:30 AM EST - 8 months ago

Altimmune Announces CEO Transition and Succession Plan

Nov 26, 2025, 7:30 AM EST - 8 months ago

Altimmune to Participate in the Piper Sandler 37th Annual Healthcare Conference

Nov 20, 2025, 3:00 AM EST - 8 months ago

Altimmune Transcript: Jefferies London Healthcare Conference 2025

Nov 13, 2025, 7:00 AM EST - 8 months ago

Altimmune Registration statement: Registration Filing

Nov 12, 2025, 10:00 AM EST - 8 months ago

Altimmune Transcript: Stifel 2025 Healthcare Conference

Nov 11, 2025, 8:51 AM EST - 8 months ago

Altimmune Announces Publication of IMPACT Phase 2b Trial Data in The Lancet and Concurrent Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2025

Nov 7, 2025, 8:05 AM EST - 8 months ago

Altimmune Presents AI-Based Analysis of Liver Fibrosis Reduction from IMPACT Phase 2b Trial of Pemvidutide in MASH in Late-breaking Poster at AASLD The Liver Meeting® 2025

Nov 6, 2025, 4:00 PM EST - 9 months ago

Altimmune Slides: Corporate Presentation

Nov 6, 2025, 8:30 AM EST - 9 months ago

Altimmune Earnings Call Transcript: Q3 2025

Nov 6, 2025, 8:30 AM EST - 9 months ago

Altimmune Quarterly report: Q3 2025

Nov 6, 2025, 8:30 AM EST - 9 months ago

Altimmune Earnings release: Q3 2025

Nov 6, 2025, 7:00 AM EST - 9 months ago

Altimmune Announces Third Quarter 2025 Financial Results and Business Updates

Nov 6, 2025, 7:00 AM EST - 9 months ago

Altimmune Registration statement: Registration Filing

Nov 5, 2025, 7:30 AM EST - 9 months ago

Altimmune to Participate in Two Upcoming Investor Conferences

Nov 3, 2025, 7:30 AM EST - 9 months ago

Altimmune Announces Early Completion of Enrollment in RECLAIM Phase 2 Trial Evaluating Pemvidutide in Alcohol Use Disorder

Oct 30, 2025, 7:30 AM EDT - 9 months ago

Altimmune to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025

Oct 21, 2025, 7:00 AM EDT - 9 months ago

Altimmune Transcript: H.C. Wainwright Liver Disease Virtual Conference

Oct 20, 2025, 7:30 AM EDT - 9 months ago

Altimmune to Present Phase 2b IMPACT Data on Pemvidutide in MASH in Late-Breaking Oral Podium Presentation and Late-Breaking Poster at AASLD The Liver Meeting® 2025

Sep 30, 2025, 10:30 AM EDT - 10 months ago

Altimmune Transcript: Stifel Virtual Cardiometabolic Forum

Sep 29, 2025, 7:30 AM EDT - 10 months ago

Altimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer to Drive Next Phase of Clinical Development of Pemvidutide

Sep 25, 2025, 8:30 AM EDT - 10 months ago

Altimmune Transcript: AGM 2025

Sep 15, 2025, 7:30 AM EDT - 10 months ago

Altimmune Appoints Accomplished Commercial Executive Linda M. Richardson as Chief Commercial Officer

Sep 10, 2025, 7:45 AM EDT - 11 months ago

Altimmune Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 9, 2025, 8:30 AM EDT - 11 months ago

Altimmune Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Aug 19, 2025, 7:30 AM EDT - 11 months ago

Altimmune Announces FDA Fast Track Designation for Pemvidutide in Alcohol Use Disorder (AUD)

denzo2 Jul. 16 at 10:48 PM

$ALT If anybody wants to buy my 4000 shares at $5 ( small profit).. let me know..thanks

2 · Reply

PashaGainz Jul. 16 at 10:05 PM

4 · Reply

Hatrak1 Jul. 16 at 9:48 PM

$ALT Sorry, had to correct the math ! 🤷‍♂️😁

1 · Reply

Hatrak1 Jul. 16 at 9:43 PM

$ALT The only thing more annoying is you ! 😁

0 · Reply

LeeroyJenkins2 Jul. 16 at 9:39 PM

$ALT

0 · Reply

LeeroyJenkins2 Jul. 16 at 9:38 PM

$ALT cheapies are expensive!

0 · Reply

Hatrak1 Jul. 16 at 9:29 PM

$ALT Yeah bro, That's pretty funny ! 🤣

1 · Reply

Chalutz Jul. 16 at 9:27 PM

$ALT The only thing more annoying is when people continually post Bought more cheapies today. Thanks for cheapies…..blah, blah, blah

0 · Reply

7Bstmde7B Jul. 16 at 9:01 PM

0 · Reply

MRD85 Jul. 16 at 9:01 PM

$ALT

0 · Reply

BioRich Jul. 16 at 8:36 PM

$GALT Against my better judgement, I bought at $4.95 after a recommendation from a colleague in the low $5's. Now down to the low 4's. Any hope here? Strictly a BO/PS/M&A trade or real value here? Is this another $ALT 2.0 or what are we legitimately looking at here? Bear/Bull feedback appreciated. Cheers!

5 · Reply

washedouttrader Jul. 16 at 8:29 PM

$ALT anemic volume.

0 · Reply

BuddyBoy6975 Jul. 16 at 8:21 PM

$ALT I’m gonna go out on a limb here. We could be REALLY close. Why…? Just blocked 4. FOUR obvious paid dissenters. Never THAT many in a single day. And ALL at the same time. These clown shows very typical ahead of good news

0 · Reply

BuddyBoy6975 Jul. 16 at 8:17 PM

$ALT Bub. Bye. 😎

1 · Reply

BuddyBoy6975 Jul. 16 at 8:16 PM

$ALT Bub. Bye. 😎

0 · Reply

BuddyBoy6975 Jul. 16 at 8:15 PM

$ALT Bub. Bye. lol

0 · Reply

BuddyBoy6975 Jul. 16 at 8:14 PM

$ALT Bub. Bye. 😎

0 · Reply

Markperk Jul. 16 at 8:10 PM

$ALT glad I sold this turd on yesterday’s bump

1 · Reply

Hatrak1 Jul. 16 at 8:01 PM

$ALT

0 · Reply

Hatrak1 Jul. 16 at 7:46 PM

$ALT I wonder if a stoned spider would output a differentiated web design ? 🤣🤷‍♂️

3 · Reply

Hatrak1 Jul. 16 at 7:40 PM

$ALT I don't get it ? Some of the folks following you are too smart not to know that you are FULL OF SHIT, ALL THE TIME ? 🤷‍♂️

4 · Reply

FSDPSK Jul. 16 at 7:25 PM

$ALT The actual truth behind brainwashed permabulls’ multi billion acquisition fantasy? 🤡 You’ve been desperately averaging down for past years, pretending each dip was the "bottom," while the stock just kept drilling to hell. Now you’re completely trapped with high cost basis with few dry powder left or none. At this point, you just need that imaginary$7-10B buyout delusion to jerk off to, because admitting Durso scammed you would mean admitting you flushed your life savings down the toilet. Keep holding that heavy-ass bag into the abyss. Durso thanks you for your donation! 🤣 💩

1 · Reply

Market Cap	569.81M
Revenue (ttm)	40,000.00
Net Income (ttm)	-88.09M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-220,225.00%
Debt to Equity Ratio	0.15

Volume	2,994,300
Avg Vol	3,762,342
Day's Range	N/A - N/A
Shares Out	194.47M
Stochastic %K	23%
Beta	0.25
Analysts	Strong Sell
Price Target	$12.95